COMPANY · NIPC 507002571

PharmaKern Portugal - Produtos Farmacêuticos Sociedade Unipessoal Lda

This page shows the public contracts the company has signed, which bodies gave them, and who it competed against.

Portal BASE records €108,471,556.10 across 1,965 contracts.

Follow (RSS) · What is RSS?

Identification

Company namePharmaKern Portugal - Produtos Farmacêuticos Sociedade Unipessoal Lda
NIPC507002571
Registered office2794-038 Carnaxide Carnaxide
SourceTED (Jornal Oficial da UE), aviso 266560-2025
Record date25 April 2025

Contracted money

Sums of the contract prices on Portal BASE. A contract with several buyers or municipalities counts once in each row, so rows do not add up to the total.

Contracted value by yearBars with the value contracted in each year, from 2013 to 2026. The table below gives the same values.2013: €24,236.9620132014: €251,226.382015: €3,252,936.6420152016: €1,633,394.482017: €2,913,448.4720172018: €6,217,843.572019: €16,338,563.5520192020: €9,252,297.132021: €11,314,978.6620212022: €13,276,600.312023: €15,963,705.4020232024: €18,416,736.182025: €9,485,762.6420252026: €129,825.73€18,416,736.18
Contracted value by year
YearContractsContract value
20132€24,236.96
201420€251,226.38
201568€3,252,936.64
2016105€1,633,394.48
2017125€2,913,448.47
2018179€6,217,843.57
2019173€16,338,563.55
2020212€9,252,297.13
2021208€11,314,978.66
2022191€13,276,600.31
2023257€15,963,705.40
2024283€18,416,736.18
2025122€9,485,762.64
202620€129,825.73
Contracted value by place of performance
NameContractsContract value
Coimbra107€20,716,291.39
Lisboa301€19,219,641.54
Setúbal114€14,813,959.91
Porto135€8,692,071.38
Almada93€4,308,304.43
Faro106€4,005,499.26
Vila Nova de Gaia91€3,553,692.24
Viseu79€3,546,392.43
Évora30€3,118,931.55
Amadora75€2,812,838.21
Largest contracts
SubjectYearContract value
Ajuste direto para aquisição de I287 , R147, R148, T1585 e T1633 (doentes em tratamento), para suprir necessidades na área da saúde.2022€3,090,365.40
Medicamentos do Foro Oncológico e Imunomoduladores2023€2,671,873.53
RITUXIMAB 500 MG/50 ML SOL INJ FR 50 ML IV2019€2,388,165
Aquisição de medicamentos do foro oncológico2015€2,193,037.86
040100762021-RITUXIMAB 500 MG/50 ML SOL INJ FR 50 ML IV2021€1,692,000

Who they competed with

In 9,601 contracts with a list of competitors, the company took part and was awarded 644 (7%).

Companies with the most procedures in common
CompanyProcedures in common
generis farmaceutica SA654
sandoz517
mylan507
farmoz482
overpharma472
labesfal, sa452
hikma379
accord healthcare unipessoal, lda375
medinfar355
fresenius355
pfizer313
alloga282
teva Pharma Produtos Farmacêuticos, Lda.252
novartis farma251
Zentiva, Lda.237
DLA-Farmacêutica,SA.226
b.braun medical215
msd203
Genéricos - Comércio de Medicamentos S.A.201
roche farmaceutica quimica162
sanofi-produtos farmaceuticos159
gsk prod. farmacêuticos148
Normon, SA147
janssen cilag farmaceutica135
bayer119
tecnimede118
Pharmis Biofarmacêutica, Lda.117
Baxter Médico Farmacêutica, Lda.117
tecnifar111
unilfarma108

The annual IMPIC file lists competitors for about 42% of contracts. Only these enter the counts, and the award share is measured on them.

Links read in contract documents

Contract documents give addresses and the names of representatives and partners, and Portal BASE and GLEIF give competitors and groups. This is what the records show; the same address or name can have simple explanations.

Links read in contract documents37 companies and 60 links. The list below gives the same content as text.bayer (NIPC 500043256)bayernovartis farma (NIPC 500063524)novartis farmasanofi-produto… (NIPC 500134960)sanofi-produto…gsk prod. farm… (NIPC 500139962)gsk prod. farm…pfizer (NIPC 500162166)pfizerjanssen cilag … (NIPC 500189412)janssen cilag …msd (NIPC 500191360)msdroche farmaceu… (NIPC 500233810)roche farmaceu…unilfarma (NIPC 500293023)unilfarmamedinfar (NIPC 500384045)medinfarPharmaKern Portugal - Pro… (NIPC 507002571)PharmaKern Portugal - Pro…+26 in the list below

Dotted: competed in the same procedure. Dotted: same procedure.

48 more links

Investigations that mention it

No published investigation mentions this company by NIPC.